Drug designed to raise HDL levels falls down

Journal of Clinical Investigation

Volumn 117, Issue 2, 2007, Pages 282-

  Honey, Karen ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TORCETRAPIB;

ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORONARY RISK; HUMAN; ISCHEMIC HEART DISEASE; MONOTHERAPY; NOTE; PRIORITY JOURNAL; STROKE;

ANTICHOLESTEREMIC AGENTS; CHOLESTEROL ESTER TRANSFER PROTEINS; DRUG INDUSTRY; HEART DISEASES; HEPTANOIC ACIDS; HUMANS; LIPOPROTEINS, HDL; PYRROLES; QUINOLINES;

EID: 33846809456     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI31253     Document Type: Note

References (5)

1. Berenson, A. 2006 December 1. Pfizer likely to seek approval of new heart drug in 2007. The New York Times. http://query.nytimes.com/gst/fullpage. html?sec=health&res=9C00EFDB1E3EF932A35751C1A9609C8B63.
2. Inazu, A., et al. 1990. Increased high-density lipoprotein levels caused by a common cholesterylester transfer protein gene mutation. N. Engl. J. Med. 323:1234-1238.
3. Zhong, S., et al. 1996. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J. Clin. Invest. 97:2917-2923.
4. Rader, D.J. 2006. Molecular regulation of HDL metabolism and function: implications for novel therapies. J. Clin. Invest. 116:3090-3100. doi:10.1172/JCI30163.
5. Berenson, A. 2006 December 4. End of drug trial is a big loss for Pfizer. The New York Times. http://www.nytimes.com/2006/12/04/health/04pfizer. html.